Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 1/20 | 0.61 |
| ▸ | SKP1 | P63208 | 1/20 | 0.61 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.61 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.55 |
| ▸ | ACACB | O00763 | 5/20 | 0.49 |
| ▸ | ACACA | Q13085 | 5/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | F10 | P00742 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38666500 | 0.83 | CKS1B (0.63) | CKS1BSKP1SKP2ACACBACACA | |
| SCHEMBL11906478 | 0.83 | CKS1B (0.63) | CKS1BSKP1SKP2ACACBACACA | |
| SCHEMBL6066417 | 0.83 | GPR119 (0.61) | CKS1BSKP1SKP2GPR119ACACB | |
| SCHEMBL21198067 | 0.82 | CKS1B (0.49) | CKS1BSKP1SKP2GPR119KDM4E | |
| SCHEMBL4528922 | 0.82 | CKS1B (0.59) | CKS1BSKP1SKP2ACACBACACA | |
| SCHEMBL29878611 | 0.81 | GPR119 (0.61) | CKS1BSKP1SKP2GPR119KDM4E | |
| SCHEMBL18886506 | 0.81 | GPR119 (0.61) | CKS1BSKP1SKP2GPR119KDM4E | |
| SCHEMBL3270009 | 0.81 | KDM4E (0.51) | GPR119KDM4EALDH1A1GAARXFP1 | |
| SCHEMBL803332 | 0.80 | CKS1B (0.56) | CKS1BSKP1SKP2KDM4EACACB | |
| SCHEMBL15786986 | 0.80 | CKS1B (0.54) | CKS1BSKP1SKP2KDM4EACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040180925-A1 | Dipeptidylpeptidase-IV inhibitor | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-09-16 | — | — | US | disclosed |
| EP-1354882-A1 | DIPEPTIDYL PEPTIDASE IV INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180925-A1 | Dipeptidylpeptidase-IV inhibitor | DPP4, DPP3, DPP9 | CKS1B 3309/4885SKP1 3880/4885SKP2 4008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.